Does the media favor STOK or ENTX?

In the previous week, Stoke Therapeutics had 12 more articles in the media than Entera Bio. MarketBeat recorded 13 mentions for Stoke Therapeutics and 1 mentions for Entera Bio. Stoke Therapeutics' average media sentiment score of 1.07 beat Entera Bio's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, NBTX or ENTX?

Entera Bio has lower revenue, but higher earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 54.92 -$27.11M N/A N/A Entera Bio $40K 12,819.96 -$11.44M -$0.35 N/A

Is NBTX or ENTX more profitable?

Nanobiotix's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Entera Bio N/A -147.19% -103.22%

Does the media refer more to NBTX or ENTX?

In the previous week, Nanobiotix had 2 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Entera Bio. Nanobiotix's average media sentiment score of 0.75 beat Entera Bio's score of 0.00 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTX or VIR?

In the previous week, Vir Biotechnology had 6 more articles in the media than Entera Bio. MarketBeat recorded 7 mentions for Vir Biotechnology and 1 mentions for Entera Bio. Vir Biotechnology's average media sentiment score of 1.07 beat Entera Bio's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ENTX or IMCR?

Entera Bio has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 12,819.96 -$11.44M -$0.35 N/A Immunocore $400.02M 4.84 -$35.51M -$0.37 N/A

Is ENTX or IMCR more profitable?

Entera Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Immunocore -4.20% -4.54% -1.66%

Does the media prefer ENTX or IMCR?

In the previous week, Immunocore had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Immunocore and 1 mentions for Entera Bio. Immunocore's average media sentiment score of 0.73 beat Entera Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LKFT or ENTX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Entera Bio N/A -147.19% -103.22%

Does the media favor LKFT or ENTX?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 1 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.00 equaled Entera Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Entera Bio (ENTX) Competitors

$2.95 +0.03 (+1.03%)

As of 09/3/2026 04:00 PM Eastern

Compare

ENTX vs. STOK, NBTX, VIR, IMCR, and LKFT

Should you buy Entera Bio stock or one of its competitors? Entera Bio's main competitors and comparable companies include Stoke Therapeutics (STOK), Nanobiotix (NBTX), Vir Biotechnology (VIR), Immunocore (IMCR), and Lakefront Biotherapeutics American Depositary Shares (LKFT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entera Bio compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Entera Bio has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Entera Bio	N/A	-147.19%	-103.22%

Stoke Therapeutics has higher revenue and earnings than Entera Bio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.49	-$6.89M	-$3.34	N/A
Entera Bio	$40K	12,819.96	-$11.44M	-$0.35	N/A

Stoke Therapeutics currently has a consensus target price of $44.25, indicating a potential upside of 47.55%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 205.08%. Given Entera Bio's higher probable upside, analysts clearly believe Entera Bio is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Stoke Therapeutics had 12 more articles in the media than Entera Bio. MarketBeat recorded 13 mentions for Stoke Therapeutics and 1 mentions for Entera Bio. Stoke Therapeutics' average media sentiment score of 1.07 beat Entera Bio's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stoke Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

14.1% of Entera Bio shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Stoke Therapeutics and Entera Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Entera Bio (NASDAQ:ENTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Nanobiotix had 2 more articles in the media than Entera Bio. MarketBeat recorded 3 mentions for Nanobiotix and 1 mentions for Entera Bio. Nanobiotix's average media sentiment score of 0.75 beat Entera Bio's score of 0.00 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential downside of 6.67%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 205.08%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has lower revenue, but higher earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	54.92	-$27.11M	N/A	N/A
Entera Bio	$40K	12,819.96	-$11.44M	-$0.35	N/A

Nanobiotix has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Entera Bio	N/A	-147.19%	-103.22%

Summary

Nanobiotix beats Entera Bio on 8 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Vir Biotechnology?

Entera Bio (NASDAQ:ENTX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 10.6% of Entera Bio shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Entera Bio has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 205.08%. Vir Biotechnology has a consensus target price of $21.57, suggesting a potential upside of 88.40%. Given Entera Bio's higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Entera Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Entera Bio has higher earnings, but lower revenue than Vir Biotechnology. Entera Bio is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,819.96	-$11.44M	-$0.35	N/A
Vir Biotechnology	$68.56M	28.26	-$437.99M	-$1.86	N/A

In the previous week, Vir Biotechnology had 6 more articles in the media than Entera Bio. MarketBeat recorded 7 mentions for Vir Biotechnology and 1 mentions for Entera Bio. Vir Biotechnology's average media sentiment score of 1.07 beat Entera Bio's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vir Biotechnology beats Entera Bio on 11 of the 17 factors compared between the two stocks.

How does Entera Bio compare to Immunocore?

Entera Bio (NASDAQ:ENTX) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Entera Bio currently has a consensus price target of $9.00, indicating a potential upside of 205.08%. Immunocore has a consensus price target of $56.38, indicating a potential upside of 50.05%. Given Entera Bio's higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

Entera Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Immunocore	-4.20%	-4.54%	-1.66%

In the previous week, Immunocore had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Immunocore and 1 mentions for Entera Bio. Immunocore's average media sentiment score of 0.73 beat Entera Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entera Bio has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,819.96	-$11.44M	-$0.35	N/A
Immunocore	$400.02M	4.84	-$35.51M	-$0.37	N/A

Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Immunocore beats Entera Bio on 9 of the 17 factors compared between the two stocks.

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $30.67, indicating a potential upside of 5.67%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 205.08%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Entera Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A
Entera Bio	$40K	12,819.96	-$11.44M	-$0.35	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Entera Bio	N/A	-147.19%	-103.22%

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 1 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.00 equaled Entera Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lakefront Biotherapeutics American Depositary Shares beats Entera Bio on 7 of the 13 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$507.60M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-8.43	12.66	273.29	25.38
Price / Sales	12,819.96	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	73.75	16.29	12.89	6.14
Net Income	-$11.44M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.64%	0.34%	0.60%	-0.27%
1 Month Performance	2.79%	8.52%	5.73%	0.68%
1 Year Performance	36.57%	52.66%	25.35%	14.84%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	1.8636 of 5 stars	$2.95 +1.0%	$9.00 +205.1%	+45.3%	$507.60M	$40K	N/A	20	Gap Up
STOK Stoke Therapeutics	3.2608 of 5 stars	$30.89 -1.0%	$44.25 +43.3%	+51.7%	$1.99B	$184.42M	N/A	100	Positive News Insider Trade
NBTX Nanobiotix	1.0981 of 5 stars	$39.29 -3.3%	$37.33 -5.0%	+362.7%	$1.99B	$36.87M	N/A	100
VIR Vir Biotechnology	2.1179 of 5 stars	$11.63 +6.3%	$21.57 +85.5%	+107.8%	$1.97B	$68.56M	N/A	580	Positive News
IMCR Immunocore	3.5748 of 5 stars	$36.86 +1.5%	$56.38 +52.9%	+6.5%	$1.90B	$400.02M	N/A	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. STOK, NBTX, VIR, IMCR, and LKFT

How does Entera Bio compare to Stoke Therapeutics?

Summary

How does Entera Bio compare to Nanobiotix?

Summary

How does Entera Bio compare to Vir Biotechnology?

Summary

How does Entera Bio compare to Immunocore?

Summary

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. STOK, NBTX, VIR, IMCR, and LKFT

How does Entera Bio compare to Stoke Therapeutics?

Is STOK or ENTX more profitable?

Which has better earnings and valuation, STOK or ENTX?

Do analysts rate STOK or ENTX?

Does the media favor STOK or ENTX?

Which has more volatility and risk, STOK or ENTX?

Do institutionals and insiders believe in STOK or ENTX?

Summary

How does Entera Bio compare to Nanobiotix?

Do institutionals & insiders hold more shares of NBTX or ENTX?

Does the media refer more to NBTX or ENTX?

Do analysts prefer NBTX or ENTX?

Which has stronger earnings & valuation, NBTX or ENTX?

Which has more volatility and risk, NBTX or ENTX?

Is NBTX or ENTX more profitable?

Summary

How does Entera Bio compare to Vir Biotechnology?

Do insiders and institutionals hold more shares of ENTX or VIR?

Is ENTX or VIR more profitable?

Do analysts prefer ENTX or VIR?

Which has more risk and volatility, ENTX or VIR?

Which has higher valuation and earnings, ENTX or VIR?

Does the media refer more to ENTX or VIR?

Summary

How does Entera Bio compare to Immunocore?

Do analysts rate ENTX or IMCR?

Is ENTX or IMCR more profitable?

Does the media prefer ENTX or IMCR?

Which has stronger earnings and valuation, ENTX or IMCR?

Which has more risk & volatility, ENTX or IMCR?

Do insiders & institutionals have more ownership in ENTX or IMCR?

Summary

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Do insiders and institutionals believe in LKFT or ENTX?

Do analysts recommend LKFT or ENTX?

Which has more risk & volatility, LKFT or ENTX?

Which has higher earnings & valuation, LKFT or ENTX?

Is LKFT or ENTX more profitable?

Does the media favor LKFT or ENTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools